PDE5A and benign prostatic hyperplasia: Tadalafil was approved in 2003 by US Food and Drug Administration (FDA) as the first and only PDE5 inhibitor clinically proven to provide sustained efficacy and in 2011, a single 5 mg daily dose was licensed to treat LUTS secondary to BPH with or without erectile dysfunction.